Compare Stocks: ABEO, JANX, MNKD, and CVAC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$4.36 -3.5%	$5.75	$4.00 ▼ $7.65	$258.47M	1.31	1.41 million shs	1.77 million shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
JANX Janux Therapeutics	$17.13 -0.3%	$17.52	$12.12 ▼ $35.34	$1.05B	2.4	962,235 shs	614,591 shs
MNKD MannKind	$3.02 -1.0%	$3.76	$2.23 ▼ $6.51	$980.71M	1.09	5.48 million shs	7.93 million shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-7.76%	-9.78%	-16.45%	-38.00%	-16.45%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.54%
JANX Janux Therapeutics	-5.34%	+2.32%	+0.47%	+7.17%	-34.65%
MNKD MannKind	-2.56%	-17.79%	-18.67%	-25.43%	-40.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$4.36 -3.5%	$5.75	$4.00 ▼ $7.65	$258.47M	1.31	1.41 million shs	1.77 million shs
CVAC CureVac	$4.66	$4.66	$3.13 ▼ $5.72	$1.05B	1.77	992,546 shs	N/A
JANX Janux Therapeutics	$17.13 -0.3%	$17.52	$12.12 ▼ $35.34	$1.05B	2.4	962,235 shs	614,591 shs
MNKD MannKind	$3.02 -1.0%	$3.76	$2.23 ▼ $6.51	$980.71M	1.09	5.48 million shs	7.93 million shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	-7.76%	-9.78%	-16.45%	-38.00%	-16.45%
CVAC CureVac	0.00%	0.00%	0.00%	0.00%	-13.54%
JANX Janux Therapeutics	-5.34%	+2.32%	+0.47%	+7.17%	-34.65%
MNKD MannKind	-2.56%	-17.79%	-18.67%	-25.43%	-40.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	2.67	Moderate Buy	$21.00	381.65% Upside
CVAC CureVac	1.00	Sell	N/A	N/A
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	112.85% Upside
MNKD MannKind	2.60	Moderate Buy	$7.84	159.73% Upside

Current Analyst Ratings Breakdown

Latest ABEO, JANX, MNKD, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/7/2026	MNKD MannKind	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$6.00 ➝ $5.00
10/5/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
10/2/2026	MNKD MannKind	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D)
9/25/2026	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/25/2026	ABEO Abeona Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/18/2026	ABEO Abeona Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$28.00 ➝ $30.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$17.00
9/17/2026	ABEO Abeona Therapeutics	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$17.00
9/11/2026	MNKD MannKind	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight	$8.00
9/3/2026	MNKD MannKind	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Peer Perform ➝ Outperform	$23.00

(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$5.82M	42.84	N/A	N/A	$2.94 per share	1.48
CVAC CureVac	$70.74M	14.78	$0.99 per share	4.73	$3.36 per share	1.39
JANX Janux Therapeutics	$10M	104.73	N/A	N/A	$15.91 per share	1.08
MNKD MannKind	$348.97M	2.78	$0.06 per share	49.29	($0.17) per share	-17.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	$71.18M	-$1.09	N/A	N/A	N/A	N/A	-41.69%	-30.36%	11/11/2026 (Estimated)
CVAC CureVac	$175.50M	$0.72	6.47	N/A	N/A	199.92%	-23.03%	-19.09%	N/A
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
MNKD MannKind	$5.86M	-$0.13	N/A	302.00	N/A	-11.08%	N/A	-6.31%	11/4/2026 (Estimated)

Latest ABEO, JANX, MNKD, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ABEO Abeona Therapeutics	-$0.14	N/A	N/A	N/A	$14.82 million	N/A
11/5/2026	Q3 2026	JANX Janux Therapeutics	-$0.4737	N/A	N/A	N/A	$8.03 million	N/A
11/4/2026	Q3 2026	MNKD MannKind	-$0.0575	N/A	N/A	N/A	$109.49 million	N/A
8/13/2026	Q2 2026	ABEO Abeona Therapeutics	-$0.2317	-$0.35	-$0.1183	-$0.35	$12.24 million	$11.38 million
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/5/2026	Q2 2026	MNKD MannKind	-$0.0075	-$0.01	-$0.0025	-$0.06	$108.08 million	$109.37 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
MNKD MannKind	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.01	6.63	6.40
CVAC CureVac	0.03	3.70	3.69
JANX Janux Therapeutics	N/A	16.35	16.35
MNKD MannKind	N/A	1.72	1.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
CVAC CureVac	17.26%
JANX Janux Therapeutics	75.39%
MNKD MannKind	49.55%

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	7.10%
CVAC CureVac	2.15%
JANX Janux Therapeutics	7.90%
MNKD MannKind	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	226	57.18 million	53.12 million	Optionable
CVAC CureVac	880	224.34 million	219.52 million	No Data
JANX Janux Therapeutics	113	61.14 million	56.31 million	Optionable
MNKD MannKind	592	321.54 million	313.18 million	Optionable

ABEO, JANX, MNKD, and CVAC Headlines

Recent News About These Companies

MannKind to Participate in the Chardan Healthcare Conference

October 14 at 4:01 PM | globenewswire.com

MannKind Corporation (NASDAQ:MNKD) Stock Has Average Target Price of $7.84 According to Brokerages

October 12 at 2:29 AM | americanbankingnews.com

MannKind Corporation (NASDAQ:MNKD) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

October 12 at 2:28 AM | marketbeat.com

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the ...

October 10, 2026 | enidnews.comE

Truist Financial Keeps Their Buy Rating on MannKind (MNKD)

October 10, 2026 | theglobeandmail.com

Mannkind Corporation Presents New Clinical Data Related to Furoscix Readyflow At Heart Failure Society of America Annual Scientific Meeting

October 10, 2026 | marketscreener.comM

MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)

October 9, 2026 | globenewswire.com

MannKind Presents New Data Showing Furoscix ReadyFlow Delivers IV-Equivalent Diuresis Across Injection Sites at HFSA 2026

October 9, 2026 | quiverquant.comQ

MannKind (NASDAQ:MNKD) Shares Down 5.1% - What's Next?

October 9, 2026 | marketbeat.com

Truist Financial Has Lowered Expectations for MannKind (NASDAQ:MNKD) Stock Price

October 9, 2026 | americanbankingnews.com

MannKind (NASDAQ:MNKD) Stock Price Target Lowered at Truist Financial

October 7, 2026 | marketbeat.com

MannKind (NASDAQ:MNKD) Stock Rating Raised to Hold at Zacks Research

October 7, 2026 | americanbankingnews.com

Zacks Research Upgrades MannKind (NASDAQ:MNKD) to "Hold"

October 7, 2026 | marketbeat.com

MannKind stock weighs 43 percent revenue growth against losses

October 5, 2026 | ad-hoc-news.deA

MannKind stock fell 3.8 percent as analysts kept a positive view

October 4, 2026 | ad-hoc-news.deA

MannKind (NASDAQ:MNKD) Shares Down 4.7% - What's Next?

October 2, 2026 | marketbeat.com

MannKind stock adds an inhaled GLP-1 licensing deal

October 1, 2026 | ad-hoc-news.deA

MannKind (NASDAQ:MNKD) Shares Climb 6.3% - Here's Why

September 30, 2026 | marketbeat.com

Steven Binder vende azioni MannKind (MNKD) per $128.477

September 29, 2026 | it.investing.com

MannKind (NASDAQ:MNKD) Director Sells $128,477.79 in Stock

September 29, 2026 | insidertrades.com

Insider Selling: MannKind (NASDAQ:MNKD) Director Sells $128,477.79 in Stock

September 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO, JANX, MNKD, and CVAC Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$4.36 -0.16 (-3.54%)

Closing price 04:00 PM Eastern

Extended Trading

$4.38 +0.01 (+0.34%)

As of 07:56 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

CureVac NASDAQ:CVAC

$4.66 0.00 (0.00%)

As of 10/13/2026

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Janux Therapeutics NASDAQ:JANX

$17.13 -0.05 (-0.29%)

Closing price 04:00 PM Eastern

Extended Trading

$17.13 0.00 (0.00%)

As of 07:30 PM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

MannKind NASDAQ:MNKD

$3.02 -0.03 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$3.03 +0.01 (+0.20%)

As of 07:59 PM Eastern

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABEO, JANX, MNKD, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABEO, JANX, MNKD, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABEO, JANX, MNKD, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO, JANX, MNKD, and CVAC Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

CureVac NASDAQ:CVAC

Janux Therapeutics NASDAQ:JANX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABEO, JANX, MNKD, and CVAC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABEO, JANX, MNKD, and CVAC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABEO, JANX, MNKD, and CVAC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABEO, JANX, MNKD, and CVAC Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

CureVac NASDAQ:CVAC

Janux Therapeutics NASDAQ:JANX

MannKind NASDAQ:MNKD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools